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ARTICLE
The viral protein corona directs viral pathogenesis
and amyloid aggregation
Kariem Ezzat 1,2, Maria Pernemalm 3, Sandra Pålsson1, Thomas C. Roberts4,5, Peter Järver1,
Aleksandra Dondalska1, Burcu Bestas2,18, Michal J. Sobkowiak6, Bettina Levänen7, Magnus Sköld8,9,
Elizabeth A. Thompson10, Osama Saher2,11, Otto K. Kari12, Tatu Lajunen 12, Eva Sverremark Ekström 1,
Caroline Nilsson13, Yevheniia Ishchenko14, Tarja Malm14, Matthew J.A. Wood4, Ultan F. Power 15,
Sergej Masich16, Anders Lindén7,9, Johan K. Sandberg 6, Janne Lehtiö 3, Anna-Lena Spetz 1,19 &
Samir EL Andaloussi2,4,17,19
Artiﬁcial nanoparticles accumulate a protein corona layer in biological ﬂuids, which sig-
niﬁcantly inﬂuences their bioactivity. As nanosized obligate intracellular parasites, viruses
share many biophysical properties with artiﬁcial nanoparticles in extracellular environments
and here we show that respiratory syncytial virus (RSV) and herpes simplex virus type 1
(HSV-1) accumulate a rich and distinctive protein corona in different biological ﬂuids.
Moreover, we show that corona pre-coating differentially affects viral infectivity and immune
cell activation. In addition, we demonstrate that viruses bind amyloidogenic peptides in their
corona and catalyze amyloid formation via surface-assisted heterogeneous nucleation.
Importantly, we show that HSV-1 catalyzes the aggregation of the amyloid β-peptide (Aβ42),
a major constituent of amyloid plaques in Alzheimer’s disease, in vitro and in animal models.
Our results highlight the viral protein corona as an acquired structural layer that is critical for
viral–host interactions and illustrate a mechanistic convergence between viral and amyloid
pathologies.
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The term “protein corona” refers to the layer of proteins thatadhere to the surfaces of nanostructures when theyencounter biological ﬂuids. Nanoparticles adsorb biomo-
lecules in biological ﬂuids due to the high free energy of their
surfaces1. The importance of the corona layer stems from the fact
that it constitutes the actual surface of interaction with biological
membranes or “what the cell sees” in the in-vivo context2.
Hundreds of proteins have been identiﬁed to confer a distinct
biological identity of nanoparticles in different microenviron-
ments depending on their size, chemistry, and surface modiﬁca-
tion (recently reviewed in ref. 3). These factors were found to be
critical determinants of the biodistribution and pharmacody-
namics of nanoparticles. On the other hand, the ability of the
surfaces of nanoparticles to partially denature certain corona
proteins exposing “cryptic epitopes” highlights the role of the
protein corona in the toxicology of nanoparticles4–6. The for-
mation of a protein corona is particularly important in the con-
text of nanoparticle interaction with amyloidogenic peptides such
as amyloid-β (Aβ42) and islet amyloid polypeptide (IAPP), which
are associated with Alzheimer’s disease (AD) and diabetes mel-
litus type 2 disease, respectively. Nanoparticles have been shown
to catalyze amyloid formation via binding of amyloidogenic
peptides in their corona, thereby increasing local peptide con-
centration and inducing conformational changes that facilitate
ﬁbril growth via a heterogenous nucleation mechanism7,8. This
surface-assisted (heterogenous) nucleation has been demon-
strated for several nanoparticles with different amyloidogenic
peptides including IAPP and Aβ429,10.
Here we studied viruses in terms of their biophysical equiva-
lence to synthetic nanoparticles in extracellular environments. As
nanosized obligate intracellular parasites, viruses lack any meta-
bolic activity outside the cell and can thus be expected to interact
with host factors in the microenvironment similar to artiﬁcial
nanoparticles. In the current work, we used well-established
techniques of nanotechnology to study the protein corona of
respiratory syncytial virus (RSV) in comparison with herpes
simplex virus type 1 (HSV-1) and synthetic liposomes. In addi-
tion, we studied the interaction of both RSV and HSV-1 with
amyloidogenic peptides.
RSV is an enveloped Orthopneumovirus with a diameter
between 100 and 300 nm, and a single-stranded negative-sense
RNA genome with 10 genes encoding 11 proteins11. It is a leading
cause of acute lower respiratory tract infections in young children
worldwide, causing up to an annual estimate of 34 million cases12.
By the second year of life, nearly 90% of children get infected with
RSV causing up to 196,000 yearly fatalities13. Reinfection with
RSV occurs throughout life, usually with mild local symptoms in
the upper airways14. However, reinfection in the elderly and
immunocompromised individuals can lead to severe clinical
disease in the lower airways. Although natural infection leads to
the production of neutralizing antibodies, the ability of these
antibodies to protect from subsequent RSV infections appears to
be incomplete15,16. Neither a vaccine nor an antiviral therapy is
yet available, except for passive immunization using the anti-RSV
monoclonal antibody palivizumab. Early vaccine trials using
formalin-inactivated RSV led to enhanced disease with up to 80%
of vaccinees being hospitalized and two dying following natural
RSV infection14,16. This led to the hypothesis that host immune
responses play an important role in the pathophysiology of air-
way disease caused by RSV.
HSV-1 is an example of another virus with high prevalence,
infecting nearly 70% of the human population17. HSV-1 is a
double-stranded DNA virus consisting of an icosahedral
nucleocapsid surrounded by tegument and envelope with virion
sizes ranging from 155 to 240 nm18. HSV-1 is a neurotropic
virus that infects peripheral sensory neurons and establishes
latency19. Latent HSV-1 is occasionally reactivated causing
peripheral pathology and under certain circumstances it can
migrate into the central nervous system causing herpes simplex
encephalitis, the most common cause of sporadic fatal viral
encephalitis19. In the context of the current work, we focused
on the presumptive role of HSV-1 in the pathology of AD. A
number of risk factors have been associated with AD, including
the E4 allele of the apolipoprotein E (Apo-E), diabetes, vascular
pathology, neuroinﬂammation, and infections20. Several recent
studies have supported the theory of a signiﬁcant role of HSV-1
in the disease21. HSV-1 DNA was found to be localized within
amyloid plaques in AD patients and HSV-1 infection has been
shown to promote neurotoxic Aβ accumulation in human
neural cells and to the formation of Aβ deposits in the brains of
infected mice22,23. Moreover, the presence of anti-HSV IgM
antibodies, which indicate HSV reactivation, is correlated with
a high risk of AD and antiherpetic treatment is correlated with
a reduced risk of developing dementia24,25. Despite these cor-
relations, the mechanism by which viruses induce amyloid
aggregation, the major pathological hallmark of AD, is
not known.
In the present study, we demonstrated that upon encountering
different biological ﬂuids, RSV accumulated extensive and dis-
tinct protein coronae compared with HSV-1 and synthetic lipo-
somes. The various coronae were dependent on the biological
ﬂuid and exerted markedly different effects on RSV infectivity
and capacity to activate monocyte-derived dendritic cells
(moDCs). Moreover, upon interaction with an amyloidogenic
peptide derived from IAPP, RSV accelerated the process of
amyloid aggregation via surface-assisted heterogenous nucleation.
This amyloid catalysis was also demonstrated for HSV-1 and the
Aβ42 peptide in vitro and in an AD animal model. Our ﬁndings
highlight the importance of viral protein corona interactions for
viral pathogenesis and provide a direct mechanistic link between
viral and amyloid pathologies.
Results
Rich and unique protein coronae for RSV and HSV-1. Based on
the extensive literature describing the signiﬁcant role of corona
factors in synthetic nanoparticle functionality, we used estab-
lished techniques to answer questions regarding RSV patho-
genicity26. Using proteomics, we assessed the RSV protein corona
proﬁles in adult human plasma (HP), juvenile (6-month-old
infants tested RSV negative at the time of sample collection) HP
(jHP), human bronchoalveolar lavage ﬂuid (BALF) from healthy
adults, rhesus macaque plasma (MP), and fetal bovine serum
(FBS). These biological ﬂuids represent different microenviron-
ments encountered by the virus in terms of tissue tropism (HP vs.
BALF), zoonosis (MP), and culturing conditions (FBS). The
biological ﬂuids were screened for antibodies against RSV using
enzyme-linked immunosorbent assay (ELISA) and both adult HP
and BALF contained high levels of anti-RSV IgG antibodies,
unlike jHP, MP, and FBS (Supplementary Fig. 1).
Viral stocks were produced in serum-free conditions to prevent
initial contamination with FBS proteins. Virions produced under
serum-free conditions were incubated with 10% v/v solutions of
different biological ﬂuids. Controls included non-infected cell
medium representing the background cellular secretome and
synthetic lipid vesicles of a size comparable to RSV (200 nm) with
positively or negatively charged surfaces. In addition, we
compared the coronae of RSV to HSV-1 to probe for differences
between different viruses of relatively similar size. After
incubation for 1 h at 37 °C, the virions were re-harvested by
centrifugation and washed twice before performing mass spectro-
metry (MS)-based proteomic analyses.
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Assessment of the proteomic data by principle component
analysis (PCA) showed that RSV and HSV-1 samples were well
separated from one another, and that the viral samples were well
separated from the control samples with the replicates clustering
together (Fig. 1 and Supplementary Fig. 2). Replicate clustering
was conﬁrmed via corresponding correlation plots for the
samples in the PCA, which showed higher correlation coefﬁcients
between the replicates within the same corona condition than
between different conditions (Supplementary Fig. 3). Notably,
both RSV and HSV-1 possessed distinctive proteomic proﬁles
depending on the biological ﬂuid (Fig. 1c and Supplementary
Fig. 2c). In addition, RSV protein corona proﬁles were different
between HP and jHP (Supplementary Fig. 2d); however, the use
of a different MS for this experiment prevents direct comparison
with the data shown in Fig. 1. The reproducibility of the corona
preparations was further assessed by calculating coefﬁcient of
variation (CV) between the replicates for each sample type. The
CVs ranged between 16% and 42% depending on sample type
(average 28%, Supplementary Fig. 3d).
In order to determine whether the most abundant corona
factors were the most abundant proteins in the biological ﬂuids,
the crude ﬂuids were also analyzed by MS. The top ten most
abundant proteins identiﬁed are presented in Table 1. Similar to
previous ﬁndings for nanoparticles27, our data showed that the
most abundant proteins in the protein corona were not
necessarily the most abundant in the biological ﬂuids. This,
together with the PCA analyses comparing RSV with HSV-1 and
the controls indicated enrichment of particular corona factors
depending on the surface properties of the virus. Moreover,
proteomic data sets were visualized by heatmap and hierarchical
clustering revealing an extensive protein corona signature for
viral samples in each biological ﬂuid (Fig. 1d). Although the
serum-free viral particles contained some host factors that were
incorporated during virus replication and budding from the cells,
the virus was able to subsequently accumulate a different set of
host factors that were dependent on the biological ﬂuid. As such,
a characteristic viral biological identity was associated with each
biological ﬂuid. The viral corona factors present on all three
replicates in each biological ﬂuid are listed in Supplementary
Data 1. In addition, the raw proteomics data are available in
Supplementary Data 2.
In addition, we used transmission electron microscopy (TEM)
to visualize the viral protein corona. A layer of factors was
observed interacting with the viral surface upon encounter with
cell membranes, which was absent in serum-free conditions
(Fig. 2a). This demonstrated that RSV accumulated a layer of
corona factors that are likely involved in cellular interactions. We
also performed cryoimmuno-electron microscopy (iEM) using
antibodies for certain proteins that were detected in the viral
corona proteomic analysis. In serum-free conditions, we used an
anti-RSV F-protein antibody. For adult HP and BALF coronae,
we used anti-human IgG and anti-surfactant protein A (SP-A)
antibodies, respectively. The bound antibodies were detected
using secondary antibodies coated with 10 nm gold nanoparticles.
As shown in Fig. 2b, corona factors were bound to the surface of
RSV and labeled with the respective antibodies. To further
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Fig. 1 RSV accumulates a rich and distinctive protein corona in different biological ﬂuids. a–c Principal component analyses (PCA) of the corona proteomic
proﬁles of RSV, HSV-1, and controls. Triplicate samples were incubated with 10% v/v solutions of each different biological ﬂuid for 1 h at 37 °C, then re-
harvested, washed, and ﬁnally analyzed by MS. Only proteins signiﬁcantly detected (FDR 1%) in all three replicates in each condition were used. NI= non-
infected supernatant, (−)Lipo= negatively charged lipid vesicles, 200 nm, (+)Lipo= positively charged lipid vesicles, 200 nm. a PCA comparing
proteomic proﬁles in human plasma (HP). b PCA comparing proteomic proﬁles in fetal bovine serum (FBS). c PCA comparing the corona proﬁles of RSV in
different biological ﬂuids; HP, FBS, MP, or BALF. d Heatmap representing the viral corona ﬁngerprints of RSV after incubation in different biological ﬂuids.
The three columns in the heatmap show three replicates. Only proteins signiﬁcantly detected (FDR 1%) in all three replicates in each condition were used.
Red and blue indicate higher and lower than the mean protein signal, respectively. Scale bars represent row Z-scores
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Table 1 Top ten proteins in the protein coronae of RSV, HSV-1, and crude biological ﬂuids
Top ten proteins
RSV+HP HSV-1+HP HP
Beta-actin-like protein 2 [ACTBL_HUMAN] Ig gamma-1 chain C region
[A0A087X079_HUMAN]
Serum albumin [ALBU_HUMAN]
Actin, cytoplasmic 1[ACTB_BOVIN] Complement C3 [CO3_HUMAN] Ig alpha-1 chain C region [IGHA1_HUMAN]
Actin, alpha skeletal muscle [ACTS_BOVIN] Complement component 3
[A0A0F6QNP7_BOVIN]
Serotransferrin [TRFE_HUMAN]
Complement C4-B [CO4B_HUMAN] Ig gamma-3 chain C region (Fragment)
[A0A075B6N8_HUMAN]
Ig alpha-2 chain C region [IGHA2_HUMAN]
Complement C4-A [CO4A_HUMAN] Envelope glycoprotein D [GD_HHV1F] Protein IGKV3-11 [A0A087WZW8_HUMAN]
Complement C3 [CO3_HUMAN] Protein IGKV3-11 [A0A087WZW8_HUMAN] Ig lambda-3 chain C regions (Fragment)
[A0A075B6L0_HUMAN]
Complement component 3
[A0A0F6QNP7_BOVIN]
Complement C4-B [CO4B_HUMAN] Ig lambda-1 chain C regions (Fragment)
[A0A075B6K8_HUMAN]
Tubulin alpha-1C chain [TBA1C_HUMAN] Complement C4-A [CO4A_HUMAN] Haptoglobin OS [HPT_HUMAN]
Nucleoprotein [NCAP_HRSVA] Tegument protein UL47 [TEG5_HHV1F] Isoform 2 of Fibrinogen alpha chain
[FIBA_HUMAN]
Glyceraldehyde-3-phosphate dehydrogenase
[G3P_HUMAN]
Envelope glycoprotein E [GE_HHV1F] Hemopexin OS [HEMO_HUMAN]
RSV+ FBS HSV-1+ FBS FBS
Actin, cytoplasmic 1 [ACTB_BOVIN] Chromatin assembly factor 1 subunit B
[A5D9H4_BOVIN]
Serum albumin [A0A140T897_BOVIN]
Beta-actin-like protein 2 [ACTBL_HUMAN] PRPF8 protein [A7Z025_BOVIN] ALB protein [B0JYQ0_BOVIN]
Actin, alpha skeletal muscle [ACTS_BOVIN] Angiotensinogen [ANGT_HUMAN] Alpha-2-HS-glycoprotein [FETUA_BOVIN]
Tubulin alpha-1C chain [TBA1C_HUMAN] Thyroglobulin [F1MPH3_BOVIN] Serotransferrin [G3X6N3_BOVIN]
Glyceraldehyde-3-phosphate dehydrogenase
[G3P_HUMAN]
Serglycin [SRGN_HUMAN] Serotransferrin [TRFE_BOVIN]
Nucleoprotein [NCAP_HRSVA] Histone H2B type 1-N [H2B1N_BOVIN] Fetuin-B [FETUB_BOVIN]
Phosphoprotein [PHOSP_HRSVA] Keratin, type II cytoskeletal [K2C6A_HUMAN] Protein AMBP [F1MMK9_BOVIN]
Tubulin alpha-4A chain [TBA4A_BOVIN] Period circadian protein homolog 3
[A0A087WV69_HUMAN]
Vitamin D-binding protein [VTDB_BOVIN]
Heat shock 70 kDa protein 1A
[HS71A_HUMAN]
Uncharacterized protein [H9H2P7_MACMU] Vitamin D-binding protein [F1N5M2_BOVIN]
Glyceraldehyde-3-phosphate dehydrogenase
[I2CWU4_MACMU]
Uncharacterized protein [F6WIY2_MACMU] Alpha-1B-glycoprotein [A1BG_BOVIN]
RSV+ BALF HSV-1+ BALF BALF
Actin, alpha skeletal muscle [ACTS_BOVIN] Tyrosine-protein kinase receptor
[F1MCM5_BOVIN]
Serum albumin [ALBU_HUMAN]
Actin, cytoplasmic 1 [ACTB_BOVIN] Chromatin assembly factor 1 subunit B
[A5D9H4_BOVIN]
Serotransferrin [TRFE_HUMAN]
Beta-actin-like protein [ACTBL_HUMAN] PRPF8 protein [A7Z025_BOVIN] Ig alpha-1 chain C region [IGHA1_HUMAN]
Phosphoprotein [PHOSP_HRSVA] Thyroglobulin [F1MPH3_BOVIN] Uteroglobin [UTER_HUMAN]
Glyceraldehyde-3-phosphate dehydrogenase
[G3P_HUMAN]
XYLT2 protein (Fragment) [A4FV62_BOVIN] Lysozyme C [LYSC_HUMAN]
Matrix protein [MATRX_HRSVA] Lactotransferrin (Fragment) [E7EQB2_HUMAN] Ig alpha-2 chain C [IGHA2_HUMAN]
Nucleoprotein OS [NCAP_HRSVA] Serum amyloid P-component [SAMP_HUMAN] Protein IGKV3-11 [A0A087WZW8_HUMAN]
Isoform 2 of Heat shock protein 75 kDa,
mitochondrial [TRAP1_HUMAN]
Angiotensinogen [ANGT_HUMAN] Antileukoproteinase [SLPI_HUMAN]
Pulmonary surfactant-associated protein A2
[SFPA2_HUMAN]
Ig lambda chain V-III region SH
[LV301_HUMAN]
Ig lambda-3 chain C regions (Fragment)
[A0A075B6L0_HUMAN]
Isoform 2 of 4F2 cell-surface antigen heavy
chain [4F2_HUMAN]
Platelet factor 4 [PLF4_HUMAN] Ig lambda-1 chain C regions (Fragment)
[A0A075B6K8_HUMAN]
RSV+MP RSV+ jHP MP
Actin, cytoplasmic 1 [ACTB_BOVIN] Apolipoprotein A-I [APOA1_HUMAN] Serum albumin (Fragment) [ALBU_MACMU]
Actin, alpha skeletal muscle [ACTS_BOVIN] Serum albumin [ALBU_HUMAN] Uncharacterized protein [G7MT40_MACMU]
Beta-actin-like protein 2 [ACTBL_HUMAN] Apolipoprotein A-II [APOA2_HUMAN] Uncharacterized protein [G7MJR4_MACMU]
Phosphoprotein [PHOSP_HRSVA] Isoform Gamma-A of Fibrinogen gamma chain
[FIBG_HUMAN]
Transferrin OS [F7DHR8_MACMU]
Tetraspanin (Fragment) [G7N5L6_MACMU] Fibrinogen beta chain [FIBB_HUMAN] Fibrinogen alpha chain [F6UZ60_MACMU]
Serum albumin (Fragment) [ALBU_MACMU] Apolipoprotein B-100 [APOB_HUMAN] Putative uncharacterized protein
[F6WR34_MACMU]
Uncharacterized protein [G7MT40_MACMU] Fibrinogen alpha chain [FIBA_HUMAN] Uncharacterized protein [F6UZ87_MACMU]
Matrix protein [MATRX_HRSVA] Actin, cytoplasmic 1 [ACTB_BOVIN] Haptoglobin isoform 2 preproprotein
[H9Z8D4_MACMU]
Glyceraldehyde-3-phosphate dehydrogenase
[G3P_HUMAN]
Beta-actin-like protein 2 [ACTBL_HUMAN] Uncharacterized protein
[A0A1D5QT02_MACMU]
Isoform 2 of 4F2 cell-surface antigen heavy
chain [4F2_HUMAN]
ALB protein [B0JYQ0_BOVIN] Hemoglobin subunit beta [HBB_MACMU]
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10192-2
4 NATURE COMMUNICATIONS |         (2019) 10:2331 | https://doi.org/10.1038/s41467-019-10192-2 | www.nature.com/naturecommunications
conﬁrm the binding of these factors, we performed western
blotting analysis on viral particles incubated with either HP or
BALF. Several bands were detected for SP-A in the BALF corona
samples and were completely lacking in the HP corona samples
(Supplementary Fig. 4a). In addition to the main SP-A bands,
several high-molecular-weight bands were also detected with the
anti-SP-A antibody. This suggested that SP-A was forming
complexes either on its own or with other corona factors. When
stained with anti-human IgG antibodies, bands were detected in
both coronae, but with higher intensity in the HP corona
compared with the BALF corona (Supplementary Fig. 4b). The
bands were normalized to the RSV G protein band, which was
used as a loading control (Supplementary Fig. 4c). Taken
together, our data demonstrated that RSV acquired a differential
protein corona layer depending on the biological ﬂuid.
Protein corona inﬂuences viral infectivity and moDC activa-
tion. To investigate whether differential corona composition
affects viral infectivity, virions produced under serum-free
conditions were pre-incubated with different biological ﬂuids
before infection of HEp-2 cells. The RSV virions were incubated
with biological ﬂuids at a protein concentration of 0.3 mg/mL
(equivalent to 5% v/v) for 1 h at 37 °C then diluted ten times in
serum-free medium before infecting the cells at ﬁnal multi-
plicity of infection (MOI) of 1. Corona pre-coating had a
signiﬁcant effect on viral infectivity as demonstrated by the
differential frequency of green ﬂuorescent protein (GFP)-
expressing cells quantiﬁed by ﬂow cytometry (Fig. 3a, b and
Supplementary Fig. 5). HP corona pre-coating signiﬁcantly
reduced infectivity compared with serum-free conditions,
whereas FBS and MP led to ﬁve- to sixfold enhancement in
infectivity. The BALF corona also enhanced infectivity, but to a
lower extent as compared with MP and FBS. Moreover, ﬂuor-
escence microscopy revealed syncytia formation of cells infec-
ted with BALF, MP, and FBS coronae (Supplementary Fig. 6).
No signiﬁcant differences in cell toxicity were observed. jHP
pre-coating, on the other hand, slightly enhanced infectivity,
but it did not reach signiﬁcance (Fig. 3b). This lack of inhibition
compared with adult HP could be attributed to the lack of anti-
RSV antibodies in the selected jHP (Supplementary Fig. 1).
Furthermore, we investigated the effect of different coronae on
the activation of human moDCs by quantifying the expression
of the maturation marker CD86. Differentiated moDCs were
infected by virions produced under serum-free conditions with
different corona pre-coatings for 4 h in serum-free conditions.
The cells were then washed and incubated in serum-containing
medium for 72 h before ﬂow cytometry analyses. Only the
BALF pre-coated virions were able to induce moDC activation
and increase CD86 expression (Fig. 3c–f). Notably, adding
BALF alone or corona-free RSV did not activate the cells,
Serum free
+Anti-F protein antibody
+HP
+Anti-Human IgG antibody
+BALF
+Anti-Surfactant protein A antibody
Serum free +HP +FBSa
b
Fig. 2 Corona factors bind to the viral surface. a Representative TEM images of HEp-2 cell sections (n= 3) after incubation for 1 h with RSV in either serum-
free medium or medium with 50% v/v of different biological ﬂuids. Compiled images of virions in close proximity to the cell-surface and black arrows point
to bound protein corona. b Representative cryoimmuno-electron microscopy images of RSV incubated in serum-free conditions or with 50% v/v of
different biological ﬂuids (n= 3) then labeled with anti-RSV F protein antibody, anti-human IgG, or anti-surfactant protein A antibody. Black arrows indicate
gold labeling. Bar= 200 nm
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showing that it was the RSV-BALF corona complex that
induced moDC activation. In addition, BALF pre-coating
enhanced infectivity in moDCs as quantiﬁed by ﬂow cyto-
metry of GFP expression (Fig. 3e, f). Altogether, this shows that
pre-incubation of virions produced under serum-free condi-
tions in different biological ﬂuids to allow a corona formation
greatly affects infectivity and the ability to induce moDC acti-
vation in a biological ﬂuid-dependent manner.
Differential RSV corona composition. The set of factors that
were only present in the HP corona and not in the other
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conditions comprised several antibodies and complement fac-
tors (Fig. 4a). Moreover, gene list enrichment analyses of HP
corona revealed an enrichment of immunological Gene
Ontology (GO) terms such as complement activation and
humoral immune response (Fig. 4b). The HP corona proteomic
proﬁle was consistent with the observed inhibition of infectivity
(neutralization), indicating that the corona characterization
methodology is representative of the actual layer of host
factors that surrounds the viral particle. Notably, despite
having comparably high levels of virus-speciﬁc IgG anti-
bodies (according to ELISA analysis, Supplementary Fig. 1),
BALF imparted opposite effects on infectivity compared with
HP (Fig. 3). At the proteomics level, GO analysis revealed that
the viral BALF corona comprised a different set of factors that
are less enriched in immunological components and more
enriched in factors related to adhesion, anchoring, protein
targeting and localization to membranes, and protein complex
binding (Fig. 4). This was further supported by the western
blotting analysis where the corona of the BALF-incubated vir-
ions was less enriched in human IgG compared with the viral
HP corona (Supplementary Fig. 4).
On the other hand, anti-RSV IgG-negative ﬂuids (FBS and
MP) enhanced viral infectivity in HEp-2 cells. The effect of
both FBS and MP corona on enhancement of RSV infectivity
was concentration-dependent as shown in Fig. 5a. Although the
FBS corona enhancement increased with concentration, the MP
effect decreased after a protein concentration of 0.3 mg/mL was
reached. This can be due to the increase of unbound corona
factors that compete with bound factors for cellular receptors.
Furthermore, we investigated the effect of corona pre-coating
with FBS and MP on viral neutralization via palivizumab,
which is a humanized monoclonal antibody directed against
the F protein of RSV. We found that the enhancing effects of
the coronae were completely lost in the presence of the
antibody, and that the antibody neutralization curves were very
simillar in the presence and the absence of the viral corona
(Fig. 5b). These data demostrated that high-afﬁnity antibodies
were able to compete out corona factors to impart host
protection. GO analysis revealed that FBS and MP coronae
were also enriched in terms such as anchoring, adhesion,
receptor binding, protein complex binding, membrane organi-
zation interspecies interaction, viral process, and mutualism
through parasitism (Fig. 5c, d).
RSV catalyzes amyloid aggregation. As nanoparticles are known
to bind amyloidogenic peptides in their coronae leading to
induction of amyloid aggregation via a heterogenous nucleation
mechanism, we next investigated whether viruses are also capable
of this particular corona interaction. We investigated the inter-
action of RSV with a model amyloidogenic peptide (NNFGAIL)
derived from the IAPP. We traced the ability of RSV to accelerate
amyloid kinetics using the well-established thioﬂavin-T (ThT)-
based methodology. The ThT dye changes its ﬂuorescence
emission spectrum upon binding to amyloid ﬁbrils and plotting
relative changes in the ﬂuorescence intensity against time illus-
trates the kinetics of the amyloid formation process28. Using the
ThT assay, we found that the presence of RSV particles sig-
niﬁcantly accelerated amyloid formation of NNFGAIL compared
with non-infected cell supernatant demonstrating that RSV acted
as a catalytic surface for amyloid aggregation (Fig. 6a). As a
control, we compared the kinetic curves of the virus-containing
medium vs. virus-free medium upon incubation with ThT alone
without a peptide. As shown in Supplementary Fig. 7a, the curves
were very similar, indicating that the relative changes that we
observed in the presence of amyloidogenic peptides are not due to
unspeciﬁc interaction of the virions with the ThT dye. In addi-
tion, extensive ﬁber networks were observed with TEM within
100 min of incubation with RSV (Fig. 6b) and some virions were
located at the tip of these ﬁbers (Fig. 6c). Moreover, RSV catalytic
activity was more efﬁcient than lipid vesicles of similar size;
however, it was dramatically reduced in the presence of 5% FBS,
indicating a competition between the peptide and other corona
factors for the viral surface (Fig. 6d). On the other hand, RSV
failed to catalyze the amyloid aggregation of GNNQQNY peptide,
which is derived from yeast prion protein (Fig. 6e). This, in turn,
indicated that such interactions are not universal to all amyloi-
dogenic peptides but display some selectivity depending on the
virus/peptide pair.
HSV-1 catalyzes Aβ42 amyloid aggregation in vitro and in vivo.
The ﬁnding that viral surfaces could serve as catalysts for amyloid
formation warranted further investigation and conﬁrmation using
another virus/peptide system. To this end, we investigated HSV-1
and the Aβ42 peptide, whose aggregation is a major hallmark of
AD. Recently, there has been an increasing body of reports sug-
gestive of a correlation between HSV-1 infection and AD,
reviewed in ref. 21. However, evidence of a direct role of HSV-1 in
the process of amyloid nucleation and subsequent ﬁbril growth is
currently lacking.
We found that HSV-1 signiﬁcantly accelerated amyloid
formation of Aβ42 compared with non-infected cell supernatant
(Fig. 7a). As a control, and similar to the RSV/NNFGAIL system,
both the virus-containing medium and virus-free medium
produced similar curves upon incubation with ThT alone without
peptide (Supplementary Fig. 7b). The catalytic activity was
reduced by the presence of FBS, also indicating a competition
at the viral surface (Fig. 7b). In addition, HSV-1 was more
efﬁcient than liposomes in accelerating the amyloid aggregation
kinetics (Fig. 7c). Furthermore, the propensity of HSV-1-
mediated amyloid catalysis was higher for the more
Fig. 3 Different protein coronae affect RSV infectivity and moDC activation. a, b RSV virions produced under serum-free conditions were pre-coated with
different coronae via pre-incubation with different biological ﬂuids prior to addition to HEp-2 cells in serum-free medium (diluted 10×) at an MOI of 1.
The frequencies of GFP+ cells were quantiﬁed by ﬂow cytometry 72 h post infection. Gating strategy and uninfected control is shown in Supplementary
Fig. 5. a Representative dot blot graphs demonstrating GFP+ cell frequency from different corona conditions. b Flow cytometry quantiﬁcation of the GFP+
cells presented as fold increase over RSV treatment in serum-free conditions (no corona). Data are presented as mean ± SEM of six replicates from two
separate experiments. Signiﬁcant differences in comparison with RSV (no corona) were assessed by non-parametric Kruskal–Wallis unpaired test followed
by Mann–Whitney test. P-value: **P≤ 0.01. c–f RSV virions produced under serum-free conditions were pre-coated with different coronae prior to
the addition to primary moDCs in serum-free conditions at MOI of 20. CD86 expression and frequencies of GFP+ cells were quantiﬁed by ﬂow cytometry
72 h post infection. c Representative histograms of CD86 expression in moDCs are shown. d CD86 mean ﬂuorescence intensity (MFI) is shown as mean
±SEM for six to eight individual donors from four separate experiments. Sucrose from the sucrose cushion used for RSV harvesting was also used as a
control. e The frequency of GFP+ cells is shown as mean ±SEM for six to eight individual donors from four separate experiments. Signiﬁcant differences
in comparison with RSV (no corona) were assessed by non-parametric Kruskal–Wallis unpaired test followed by Mann–Whitney test. P-value: **P≤ 0.01
and *P≤ 0.05. f Representative dot blot graphs demonstrating GFP+ moDCs frequency from different corona conditions
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amyloidogenic Aβ42 peptide compared with the shorter, less
amyloidogenic Aβ40 peptide (Fig. 7d). Amyloid induction was
further conﬁrmed by TEM demonstrating ﬁbril formation within
100 min of incubation with viral particles (Fig. 7e–h). Amyloid
protoﬁlaments and ﬁbrils at different stages of elongation were
observed interacting with the viral surface. Figure 7e and f show
multiple ﬁbrillary structures emerging from one viral particle,
suggesting that a nucleation mechanism was taking place on the
surface, thereby sparking ﬁbril elongation. Viral particles also
interacted with ﬁbrillar structures that are part of an extensive
network of ﬁbers as shown in Fig. 7g, h. Importantly, to
demonstrate the in-vivo relevance of our mechanistic ﬁndings, we
intracranially infected transgenic 5XFAD mice with HSV-1. The
5XFAD mouse is a widely used AD model, as it recapitulates
many AD phenotypes with rapid onset of Aβ42 aggregation that
spreads to the hippocampus and cortex by 6 months of age29. We
observed a signiﬁcant increase in Aβ42 accumulation in the
hippocampi and cortices of HSV-1-infected mice 48 h post
infection (Fig. 7i) in comparison with animals injected with non-
infected supernatant. Representative images of the amyloid
staining demonstrate the dramatic difference in amyloid
accumulation between infected and non-infected animals (Fig. 7j).
These results validated our biophysical ﬁndings using the ThT
assay and demonstrated that the viral corona-driven catalysis of
amyloid aggregation could take place in in-vivo situations.
Discussion
Viruses rely on the cellular machinery of the host for replication,
production of viral proteins, assembly, and export out of the cell.
However, outside cells, viruses share many biophysical properties
with artiﬁcial nanoparticles. Based on this biophysical equiva-
lence, we hypothesized that viruses accumulate a rich and selec-
tive protein corona layer in the extracellular environment similar
to nanoparticles. Examples of particular host factors that bind to
viral surfaces have previously been described. For example,
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lipoproteins such as Apo-E were shown to be essential for
hepatitis C virus infection30. Furthermore, coagulation factors
such as factor X were shown to directly bind adenovirus leading
to liver tropism31,32. Other soluble components such as Gas6
were shown to contribute to the infectivity of lentiviral vectors
even when pseudotyped with multiple types of envelope pro-
teins33. Furthermore, soluble heparin sulfonated proteoglycans
were shown to enhance the infectivity of human papilloma-
virus34. Interestingly, amyloids derived from prostatic acidic
phosphatase in semen were shown to enhance HIV-1 infectivity
by several orders of magnitude35. In addition, plant viral nano-
particles that are used for drug delivery were shown to possess a
protein corona that affects their uptake and biodistribution36.
However, to our knowledge, there is no previous work that has
characterized the protein corona of an infectious animal virus in
different biological ﬂuids and studied its effect on viral
pathogenicity.
In this work, we used proteomics to study viral protein corona
enrichment in different biological ﬂuids. We investigated the RSV
protein coronae in biological ﬂuids that are relevant to viral
tropism, zoonosis, and culturing conditions. As RSV is a virus
tropic to the respiratory tract, we compared the viral corona in
human BALF vs. HP from adult healthy volunteers and jHP from
RSV-seronegative 6-month-old infants. We also investigated the
RSV corona in plasma from rhesus macaques, which are used as
models in RSV studies and vaccine development37. Moreover, we
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studied the corona in FBS, which is the most commonly used cell
growth supplement for viral production and in-vitro studies. We
compared the RSV corona with HSV-1 and lipid vesicles of
similar size with positively or negatively charged surfaces, as well
as the biological ﬂuids per se. PCA, quantitative intra-sample
variability analysis, and correlation matrices demonstrated that
the RSV corona proﬁles were well separated from that of HSV-1
and lipid vesicles (Fig. 1 and Supplementary Figs. 2 and 3). Intra-
sample variability could arise in the process of sample preparation
during incubation, washing, and digestion or during mass
spectroscopy-based detection38. Notably, although the viral cor-
ona proﬁle was dependent on the biological ﬂuid, it was not a
mere reﬂection of the most abundant proteins, as demonstrated
earlier for nanoparticles27 and as shown in the Table 1 of the top
ten proteins present in the viral coronae in comparison with
crude biological ﬂuids. The viral protein corona was visualized
using TEM, which revealed a layer surrounding the viral surface
involved in cellular interactions (Fig. 2a). Using iEM and western
blotting, we could detect speciﬁc proteins identiﬁed from the
proteomic analysis (human IgG in HP and SP-A in BALF)
associated with RSV upon incubation with HP or BALF,
respectively (Fig. 2b and Supplementary Fig. 4). Functionally, the
coronae from the different biological ﬂuids enhanced RSV
infectivity, except for the HP corona, which completely neu-
tralized the virus (Fig. 3). Taken together, using several com-
plementary methods, our data demonstrated the speciﬁc
enrichment of differential corona proﬁles on viral surfaces. As
such, the protein corona represents an initial phase of viral–host
interactions that precedes cellular interaction and affects sub-
sequent infectivity. Unlike the viral genome-coded surface pro-
teins, the viral protein corona is an acquired structural layer that
is dependent on the viral microenvironment resulting in different
viral identities based on the target tissue and the target organism.
Moreover, as the corona layer is a rich and complex layer, the
ﬁnal biological effect is expected to be dependent on a multitude
of corona factors rather than a single protein.
Proteomic analysis of the HP corona revealed that it was
enriched in antibodies and complement factors, which could
explain the neutralization effect (Figs. 3 and 4). Other factors of
documented immunological functions such as ﬁbrinogen39,
properdin40, annexin A141, protein S10042, and vimentin43 were
also detected in the HP corona (Supplementary Data 1). These
factors could be parts of an immunological corona that enables
efﬁcient viral neutralization and/or immune system modulation.
On the other hand, jHP, which lacked the anti-RSV antibodies,
failed to neutralize the virus and the jHP corona was less enriched
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in immunological factors compared with the HP corona (Table 1
and Fig. 3). Interestingly, the BALF corona enhanced viral
infectivity in both HEp-2 cells and moDCs, despite having equally
high anti-RSV IgG antibody titers as compared with HP
according to ELISA analysis (Supplementary Fig. 1). The pro-
teomic and GO analysis showed that the BALF corona was less
enriched in immunological factors (Fig. 4). In addition, less IgG
was detected in the BALF corona in the western blotting analysis
(Supplementary Fig. 4). The failure of BALF to neutralize the
virus despite being rich in anti-RSV antibodies suggested that the
differential protein corona proﬁle could affect antibody binding
in BALF conditions. This might explain the recurrence of pul-
monary RSV infection even in individuals with high IgG titers15.
An alternative explanation is that the BALF anti-RSV antibodies
are of lower afﬁnity than their HP counterparts and are thus less
able to compete out other corona factors that enhance viral
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infectivity. It remains to be elucidated which avidity is required in
order to compete out the corona layer. The list of proteins that
were uniquely detected in the BALF corona included pulmonary
surfactants that are known to enhance RSV infectivity44,
nucleolin, and epidermal growth factor receptor (EGFR), which
were shown to be important for RSV cell entry45,46, adhesion
molecules (such as tetraspanin, neuroplastin, integrin, and cad-
herin), coxsackievirus/adenovirus receptor, poliovirus receptor,
and zinc ﬁnger CCCH-type antiviral protein 1 (Fig. 4). Notably,
pre-incubation of RSV with BALF was the only condition that
induced moDC activation (Fig. 3). Importantly, it was not the
combination of the proteins in the biological ﬂuids or the virus
per se that affected the outcome, but rather the viral–corona
complex, as shown by the lack of moDC activation by BALF or
RSV alone. Moreover, and in accordance with the documented
role of corona factors in nanoparticle immunogenicity47, our
results demonstrated the role of the acquired corona layer in
virus-induced immune activation that might contribute to disease
pathophysiology. It can be speculated that the viral corona factors
are part of the pathogen-associated molecular patterns, which are
recognized by the innate immune system. It also suggests that
corona factors need to be considered in the design of vaccines and
adjuvants for efﬁcient stimulation of the immune system.
Additional biological ﬂuids investigated in our study included
FBS and MP, and they both enhanced the infectivity of RSV in a
concentration-dependent manner (Fig. 5a). Artiﬁcially adding
anti-RSV antibodies (palivizumab) successfully neutralized the
virus even in these corona conditions, indicating successful out-
competition by the antibody (Fig. 5b). GO analysis suggested a
role of FBS and MP corona factors in interspecies interaction,
mutualism, viral process, protein complex binding, unfolded
protein binding, anchoring, and adhesion (Fig. 5c, d). Factors
uniquely present in the FBS corona that may contribute to these
effects include C4b-binding protein α-like, which is a comple-
ment inhibitor, isoform 2 of fermitin family homolog 2, which
binds to membranes enriched in phosphoinositides and enhances
integrin-mediated adhesion48 and hepatitis A virus cellular
receptor 1 (Fig. 5c). In the MP corona, several adhesion proteins
were found including the following: ﬁbronectin isoform 4 pre-
proprotein, endothelial cell-selective adhesion molecule, fermitin
family homolog 3 short form, and zyxin. The MP corona also
contained receptor ligands such as the following: transferrin and
C-X-C motif chemokine together with tetherin (isoform 2 of bone
marrow stromal antigen 2), which possesses antiviral proper-
ties49. Taken together, this illustrated that the observed functional
effects of the viral protein corona were most likely mediated by a
combination of factors that are enriched on the viral surface and
not by a single factor. As many viruses bind to several receptors
and co-receptors, such interactions might be taking place in a
multivalent manner50. In addition, our results also highlight that
the viral protein corona has to be taken into consideration in
relation to zoonosis and applications involving viral propagation
in vitro.
We then investigated whether viral corona interactions with
host factors involve surface-assisted nucleation of amyloids.
Nanoparticles have been shown to act as catalytic surfaces that
facilitate heterogenous nucleation of amyloid ﬁbrils via binding,
concentrating, and enabling conformational changes of amyloi-
dogenic peptides7,51,52. Similar to what have been reported with
nanoparticles, we found that RSV accelerated the kinetics of
amyloid aggregation of a model amyloidogenic peptide derived
from IAPP (NNFGAIL). This demonstrated that viral particles
are also capable of amyloid catalysis via surface-assisted hetero-
genous nucleation (Fig. 6). In order to investigate whether this
catalytic mechanism extends to other virus-amyloid pairs, we
evaluated whether HSV-1 could accelerate the amyloid kinetics of
Aβ42, which is implicated in AD. Several recent studies have
suggested HSV-1 involvement in AD53. Herein, we found that
HSV-1 accelerated the kinetics of amyloid aggregation of Aβ42
and, to a lesser extent, the aggregation of Aβ40 (Fig. 7). HSV-1
was more efﬁcient than lipid vesicles in amyloid catalysis and this
efﬁciency decreased in the presence of FBS demonstrating a
competition with other corona factors on the viral surface. In
addition, TEM demonstrated an interaction between amyloid
ﬁbrils at different stages of maturation and the viral surface via
early protoﬁbrillar intermediates, which we speculate represent
the surface-assisted nucleation process. Importantly, infecting
5XFAD AD animal models with HSV-1 lead to increased accu-
mulation of Aβ42 plaques as evident by immunohistochemical
analysis (Fig. 7), demonstrating that the viral corona-driven
catalysis can take place in vivo.
Taken together, our data on RSV and HSV-1 demonstrated
that viruses can physically act as nano-surfaces capable of cata-
lyzing amyloid nucleation and leading to accelerated ﬁbril for-
mation. Although our results do not prove disease causality, they
present mechanistic explanation of the clinical and experimental
correlations drawn between HSV-1 and AD, which requires
further investigation. Interestingly, Apo-E, which is a well-known
risk factor for AD, was enriched in the HSV-1 corona, suggesting
even further disease links (Supplementary Data 1).
Several recent studies have suggested that Aβ42 is an anti-
microbial peptide that aggregates to sequester pathogens54–57.
Here we present an alternative but not mutually exclusive
explanation. Our corona-driven hypothesis suggests that the virus
interacts with extracellular amyloidogenic peptides as part of the
pathogenesis and the bound peptides do not necessarily possess
an immunological and/or an antimicrobial function. This is fur-
ther corroborated by studies showing that amyloids can enhance
Fig. 7 HSV-1 accelerates the kinetics of Aβ42 ﬁbrillation invitro and in vivo. a Aβ42 peptide was incubated with ThT solution and HSV-1 (2 × 108 PFU/mL),
non-infected supernatant or DMEM serum-free growth medium. ThT ﬂuorescence was measured at 440 nm excitation and 480 nm emission over 24 h at
37 °C. b Aβ42 incubated with HSV-1 in the presence or absence of 5% FBS. c Aβ42 incubated with either HSV-1 or lipid vesicles (positively or negatively
charged, dimeter= 200 nm, concentration= 1 × 1010 particles/mL) incubated with Aβ42 peptide. d HSV-1 and DMEM serum-free growth medium
incubated with Aβ42 or Aβ40 peptides. For all the curves, means ± SEM of six replicates from two separate experiments are shown. e–h Negatively stained
TEM images of HSV-1 incubated with 50 µM Aβ42 for 100min at 37 °C. White arrows indicate viral particles and black arrows indicate ﬁbrillar structures.
e Three protoﬁlaments/ﬁbrils stemming from one viral particle, bar= 200 nm. f Two protoﬁlaments/ﬁbrils stemming from a viral particle interacting
with an aggregated structure, bar= 100 nm. g A viral particle interacting with protoﬁlaments/ﬁbrils, which are connected to extensive ﬁbrillar structures,
bar= 1 µm. h A rectangular close-up of viral interaction, bar= 500 nm. i–j Three-month-old transgenic 5XFAD mice were intracranially injected with HSV-1
or non-infected supernatant (NI). The brains were cryosectioned 48 h postinfection and stained using primary antibody speciﬁc to isoforms Aβ 37–42 and
then visualized by ﬂuorescent Alexa 568 secondary antibody. i Hippocampal and cortical Aβ immunoreactivities were quantiﬁed from six stained sections
and are presented as positive area fraction percent. N= 8 in the HSV-1 group and N= 7 in the NI group. Data are shown as mean positive area fraction
percent ±SEM from two separate experiments. Signiﬁcant differences were assessed by non-parametric Kruskal–Wallis unpaired test followed by
Mann–Whitney test and are indicated by ***P < 0.001. j Representative images of the Aβ staining from HSV-1 vs. NI mice. Bar= 500 µm
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the infectivity for viruses such as HIV and HSV35,58, and the fact
that amyloid precursor protein knockout animals are not more
susceptible for infections compared with wild-type animals59.
From this perspective, virus surface-assisted nucleation might
have evolved as a mechanism by which viruses modulate the
host’s extracellular environment by catalyzing the phase transi-
tion of certain peptides from soluble to insoluble forms; a phase
change that could lead to toxic gain or loss of function, or both. In
addition, the viral surface-assisted nucleation mechanism could
be extended to other viruses correlated with neurodegenerative
pathology such as HIV and HIV-associated neurocognitive dis-
order60, and inﬂuenza virus and post-encephalitic parkinson-
ism61, and others. Furthermore, the phenomenon of amyloid
polymorphism62 might in part be related to the different
nucleation mechanisms, where we hypothesize that the viral-
catalyzed heterogeneously nucleated amyloids would be poly-
morphically distinct from homogeneously nucleated amyloids
that result from aberrant protein expression/overexpression. This
hypothesis can be tested in future studies on the Aβ poly-
morphism in familial and sporadic AD63, and whether this
structural polymorphism can be traced back to different nuclea-
tion mechanisms related to different etiologies. Finally, the
implication that viruses are capable of inducing conformational
changes in bound host factors leading to exposure of cryptic
epitopes may prove important for better understanding the cor-
relation between viruses and autoimmune diseases.
To conclude, the current work was based on the biophysical
equivalence between viruses and artiﬁcial nanoparticles in
extracellular environments. We here demonstrated that nano-
technological concepts such as the protein corona and surface-
assisted nucleation can be extended to infectious viruses. We
showed that viral protein corona accumulation and amyloid
catalysis are two aspects of the same phenomenon, namely viral
surface interaction with extracellular host proteins. This phe-
nomenon leads to the modulation of how viruses interact with
cells and/or the induction of conformational changes in bound
proteins that leads to accelerated amyloid aggregation. These
ﬁndings highlight the potentially critical role of viral extracellular
interactions in viral infectivity and in relation to extracellular
protein pathology.
Methods
Viral and cell culture. HEp-2 cells, a human laryngeal carcinoma cell line, were
used for RSV culture and infectivity experiments. Preparation of RSV-A2-GFP
stocks was performed using VP-SFM serum-free, ultra-low protein medium con-
taining no proteins, peptides, or other components of animal or human origin
(ThermoFisher, USA). HEp-2 cells were initially seeded in growth medium (Dul-
becco’s modiﬁed Eagle’s medium (DMEM) with 5% FBS (ThermoFisher, USA), 1%
Penicillin/Streptomycin (ThermoFisher, USA), and 0.01 M HEPES (Sigma-Aldrich,
Germany) until they reached ~70–80% conﬂuency. At the day of infection, the cells
were washed twice with warm phosphate-buffered saline (PBS) and the medium
was replaced with VP-SFM containing 50 µg/mL gentamycin. Cells were infected at
MOI of 4 and incubated for 5–6 days until >90% GFP expression was visible with
ﬂuorescence microscopy. Cells were then scraped, vortexed thoroughly, sonicated
for 10 min, vortexed thoroughly one more time, and spun at 1000 × g for 5 min.
The supernatant was transferred to new tubes and used freshly for the proteomics
and amyloid interaction experiments. For long-term storage, infectivity, and moDC
activation experiments, the supernatant was adjusted with MgSO4 and HEPES
(SigmaAldrich, Germany) solutions to a ﬁnal concentration of 0.1 M MgSO4 and
50 mM HEPES. RSV was then concentrated using a 1.45 M sucrose cushions in the
following buffer (1 M MgSO4, 50 mM Hepes pH 7.5, 150 mM NaCl) according to
ref. 64 via centrifugation for 4 h at 7500 × g at 4 °C. The viral concentrated layer was
then collected from the interface between the cushion and the supernatant, ali-
quoted, and immediately frozen at −80 °C. Quantiﬁcations of viruses were per-
formed using real-time quantitative PCR (qPCR). Puriﬁcation of viral RNA was
performed using the QIAamp® Viral RNA extraction kit (QIAGEN) and extracted
RNA was stored at −80 °C. Viral titers were determined using the SuperScript® III
Platinum® One-Step Quantitative real-time PCR system (Life Technologies) with
the following probe and primers: RSV-A probe 5′-CAC CAT CCA ACG GAG
CAC AGG AGA T-3′ (5′ labeled with 6-FAM and 3′ labeled with BHQ1), RSV-A
forward primer 5′-AGA TCA ACT TCT GTC ATC CAG CAA-3′, and RSV-A
reverse 5′-TTC TGC ACA TCA TAA TTA GGA G-3′. For initial viral quantiﬁ-
cation purposes, a commercially available RSV-A2 strain was purchased (Advanced
Biotechnologies, Inc.). The MOIs used for infectivity experiments were based on
genome copies/mL measured by qPCR and the infectious viral titers were measured
as TCID50 on HEp-2 cells. Brieﬂy, tenfold dilutions of virus were added onto Hep2
cells for 2 h at 37 °C, then inoculum was removed, and fresh maintenance medium
was added. The plates were examined in the microscope on day 7 and the number
of wells for each dilution that was positive for GFP was noted. The titer was
calculated according to the method of Karber. The viral stock of 7 × 108 genome
copies/mL corresponded to log10 6.7 TCID50/mL.
For HSV-1, strain F HSV-1 stocks were prepared by infecting African green
monkey kidney (VERO) cells at 80–90% conﬂuency in DMEM (Invitrogen) with
5% FBS or in serum-free DMEM. The virus was collected 2 days after infection.
Cells were subjected to two freeze–thaw cycles and spun at 20,000 × g for 10 min to
remove cell debris. Clariﬁed supernatant was aliquoted and stored at −80 °C until
use. Non-infected cell medium was prepared with the same procedure without viral
infection. Plaque assay was used to determine viral titers. Tenfold dilutions of virus
were added onto VERO cells for 1 h at 37 °C, then inoculum was removed and
fresh medium containing 0.5% carboxymethyl cellulose (Sigma-Aldrich) was
added. Cells were ﬁxed and stained 2 days later with a 0.1% crystal violet solution
and the number of plaques was counted.
Human BALF samples. The use of human BALF samples for the current study was
approved by the Regional Committee for Ethical Review in Stockholm (D. No
2016/1985–32). All donors had given oral and written informed consent to par-
ticipate in the bronchoscopy study, in line with the Helsinki Declaration. Brieﬂy,
healthy subjects of male and female gender were recruited at the Department of
Respiratory Medicine and Allergy, Karolinska University Hospital, Solna. These
subjects were examined after denying regular tobacco smoking and history of
allergy or lung disease during an interview. The ﬁnal inclusion required that
these subjects displayed no signs of pulmonary or disease during clinical exam-
ination, spirometry, and clinical blood testing including electrolytes, white cell
differential counts, and C-reactive protein. Bronchoscopy with bronchioalveolar
lavage (5 × 50 mL of sterile and PBS) was performed according to clinical routine at
Karolinska University Hospital, Solna. The obtained BALF was concentrated using
5 kDa cutoff 4 mL spin concentrator (Agilent Technologies, USA) before infectivity
experiments.
Lipid vesicle preparation and characterization. 1,2-Distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP),
1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG), and cholesterol
were bought from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). All other
compounds were bought from Sigma-Aldrich (St. Louis, MO, USA). The lipids
were dissolved in chloroform in molar ratios of 9:1 (DSPC/cholesterol) for neutral
liposomes, 9:1 (DSPC/DOTAP) for cationic liposomes, and 9:1 (DSPC/DSPG) for
anionic liposomes. The liposomes were formed by the thin ﬁlm hydration method
followed by extrusion through a polycarbonate membrane. Brieﬂy, chloroform was
evaporated by heating the sample tube to 65 °C and gradually reducing the pressure
to 70 mbar under a nitrogen ﬂow in a vacuum rotary evaporation system (Büchi R-
114, Büchi Labortechnik AG, Flawil, Switzerland). The resulting thin lipid layer
was hydrated with 500 μL of PBS by gently stirring the tube in a water bath (65 °C)
for 1 h. The sample was then extruded 11 times (65 °C) through polycarbonate
membrane (pore size of 200 nm) with a syringe extrusion device (Avanti Polar
Lipids) after which the sample was quickly cooled down and stored in a refrig-
erator. The concentration of the samples was 19 µmol/mL. The size of the lipo-
somes was analyzed with a Zetasizer APS dynamic light-scattering automated plate
sampler (Malvern Instruments, Malvern, UK). The concentration of liposomes was
determined using Nanosight (Malvern, USA). The zeta potential was measured at
25 °C in DTS 1070 folded capillary cells with Zetasizer Nano ZS (Malvern
Instruments).
Protein corona proteomics. FBS was obtained commercially (ThermoFisher,
USA). HP was obtained and pooled from at least three different healthy donors.
jHP was obtained and pooled from at least three different infants participating in a
prospective cohort of 281 children born into the cohort between 1997 and 2000 in
Stockholm, Sweden. The study was approved by the Human Ethics Committee at
Huddinge University Hospital, Stockholm (Dnr 75/97). MP was obtained and
pooled from at least three different Indian rhesus macaques that were RSV ser-
onegative. Ethical permit Dnr N2/15, Department of Medicine, Karolinska Uni-
versity Hospital, Solna. All protein corona experiments described below were
performed in technical triplicates. For the viral corona proteomic experiments,
freshly harvested serum-free RSV supernatant (not-sucrose cushion concentrated)
containing 6.6 × 109 RSV genome equivalents or serum-free DMEM produced
HSV-1 stocks (2.1 × 108 PFU/mL) was incubated with 10% v/v solutions of dif-
ferent biological ﬂuids in for 1 h at 37 °C. Before adding the viruses, all the bio-
logical ﬂuid solutions were adjusted to 10 mM sodium citrate (SigmaAldrich,
Germany) to prevent coagulation. As a control, uninfected cell supernatant pre-
pared in a similar way was also incubated with the biological ﬂuid solutions. For
lipid vesicles, 3 × 1011 of 200 nm positively or negatively charged lipid vesicles were
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10192-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2331 | https://doi.org/10.1038/s41467-019-10192-2 | www.nature.com/naturecommunications 13
incubated with 10% v/v solutions of biological ﬂuids at similar conditions. After
incubation, viral/nanoparticle corona complexes were spun at 20,000 × g at 4 °C for
1 h, supernatant removed, and the pellet resuspended in 1 mL PBS. The pellet was
washed twice with PBS using the same centrifugation conditions, then boiled at 95 °
C for 5 min before measuring the protein content using Micro BCA™ protein assay
kit (ThermoFisher, USA). The viral/nanoparticle corona complexes were then
resuspended in PBS and adjusted with ammonium bicarbonate to a ﬁnal con-
centration of 20 mM. The samples were reduced by addition of 1:20 v/v 100 mM
dithiothreitol for 45 min at 56 °C and alkylated with 1:20 v/v 100 mM iodoaceta-
mide (IAA) for 45 min at room temperature (RT) in the dark. Proteins were
digested with trypsin (MS gold, Promega) 0.1 µg/µL overnight at 37 °C (trypsin:
protein ratio 1:50). For sample clean-up, the samples were applied to strong cation
exchange SCX microcolumns (Strata-XC Phenomenex). The microcolumns were
initially washed with 100% methanol followed by MilliQ grade water. The samples
were adjusted to >0.1% formic acid and then applied to the columns. After washing
with 30% methanol and 0.1% formic acid, the samples were eluted with 30%
methanol and 5% ammonium hydroxide. Samples were dried in a SpeedVac and
submitted to MS. For MS analysis, samples were dissolved in 3% ACN, 0.1% formic
acid to a ﬁnal concentration of 1 µg/µL. One to 2 µL of sample were analyzed with a
hybrid LTQ-Orbitrap Velos or with an Orbitrap Fusion Tribrid Mass Spectrometer
(ThermoFisher, USA). For the Velos system, an Agilent HPLC 1200 system
(Agilent) was used to provide the 70 min gradient. Data-dependent MS/MS
(centroid mode) followed in two stages: ﬁrst, the top ﬁve ions from the master scan
were selected for collision-induced dissociation with detection in the ion trap mass
spectrometry (ITMS) and then the same ﬁve ions underwent higher energy colli-
sion dissociation (HCD) with detection in the Orbitrap Fourier transform mass
spectrometry (FTMS). For the Fusion system, an UltiMate 3000 UHPLC System
was used to provide the 70 min gradient. Data-dependent MS/MS (centroid mode)
followed in two stages: ﬁrst, the top ten ions from the master scan were selected for
collision-induced dissociation with detection in the ITMS and then the same ten
ions underwent HCD with detection in the Orbitrap (FTMS). The data were
searched by Sequest under the Proteome Discoverer 1.4.1.1.4 software (Thermo-
Fisher) against the following Uniprot protein sequence databases; bos taurus ver-
sion 170310, rhesus macaque version 170704, human version 160210, RSV version
160210, HHV1 version 180613, and Chlorocebus sabaeus version 180613 using a
1% peptide false discovery rate (FDR) cutoff limit. For samples containing proteins
from multiple species, combined species databases were created by merging the
corresponding protein databases. For label-free quantiﬁcation, protein MS1 pre-
cursor area was calculated as the average of the top three most intense peptides.
Only proteins signiﬁcantly detected (FDR 1%) in all three technical replicates in
each sample were used in the downstream data analysis.
Data analysis. Only proteins signiﬁcantly detected (FDR 1%) in all three technical
replicates in each sample were used in the data analysis. PCA analysis and hier-
archical clustering of the ﬁltered proteomics data (described above) was performed
using ClustVis (https://biit.cs.ut.ee/clustvis_large/). GO gene list enrichment ana-
lysis was performed using ToppFun (https://toppgene.cchmc.org/enrichment.jsp).
Average CV was calculated for each sample based on protein precursor area.
Spearman’s correlation matrices were performed using Morpheus software based
on precursor area of proteins signiﬁcantly detected (FDR 1%) in all three technical
replicates in each sample (https://software.broadinstitute.org/morpheus). For other
experiments, non-parametric Kruskal–Wallis unpaired test was used followed by
Mann–Whitney test or Dunn’s post test, to compare the data. There were six
replicates from two independent experiments. Statistics were calculated using
GraphPad Prism 7 software.
Enzyme-linked immunosorbent assay. The detection of speciﬁc anti-RSV IgG
antibodies in biological ﬂuids was performed using Human Anti-Respiratory
syncytial virus IgG ELISA Kit (ab108765, abcam®, Sweden), according to the
manufacturer’s protocol. All biological ﬂuids (FBS, HP, MP, and BALF) were
diluted to a protein concentration of 0.3 mg/mL before performing the assay and
results were compared with the positive, cutoff and negative controls provided by
the kit manufacturer.
RSV infectivity. HEp-2 cells were seeded in maintenance medium until they
reached 50–60% conﬂuency. On the day of infection, the cells were washed twice
with warm PBS and medium was changed to VP-SFM with gentamycin. Before
adding to the cells, sucrose cushion-concentrated RSV stocks were pre-incubated
with different biological ﬂuids (FBS, HP, MP, and BALF) at a ﬁnal protein con-
centration of 0.3 mg/mL in VP-SFM with 10 mM sodium citrate for 1 h at 37 °C.
The corona-pre-coated viruses were then added to the cells in serum-free condi-
tions (diluted 10×) at a MOI of 1. 24 h post infection, the medium was changed
back to growth medium, and cells were visualized with ﬂuorescence microscopy
72 h post infection. After visualization, the cells were washed and stained with
LIVE/DEAD™ Fixable Far Red Dead Cell Stain Kit (ThermoFisher, USA) for
30 min at 4 °C in Dulbecco’s PBS (DPBS no calcium, no magnesium, Thermo-
Fisher), then ﬁxed and washed for ﬂow cytometry using Cytoﬁx/Cytoperm™
(BD, USA) according to manufacturer’s protocol. Cells were then scraped and
resuspended in DPBS and the data were acquired using MACSQuant® Analyser
10 ﬂowcytometer (Miltenyi Biotec, Sweden). The data were analyzed by FlowJo
software (TreeStar), by excluding the dead cells stained with far-red ﬂuorescent dye
and subsequent calculation of GFP-positive cells within the viable cell population.
For experiments with palivizumab, cells were treated with different concentrations
of the antibody before infection.
MoDC differentiation. Human monocytes were negatively selected from buffy
coats using the RosetteSep Monocyte Enrichment Kit (1 mL/10 mL buffy coat;
StemCell Technologies) and differentiated into moDC, using granulocyte-
machrophage colony-stimulating factor (250 ng/mL; PeproTech) and interleukin-4
(6.5 ng/mL; R&D Systems) for 6 days in 37 °C, 5% CO2 at a density of 5 × 105 cells/
mL in RPMI 1640 completed with 10% FCS, 1 mM sodium pyruvate, 10 mM
HEPES, 2 mM L-glutamine, and 1% penicillin/streptomycin (ThermoFisher, USA).
Immature moDC were exposed to RSV pre-incubated with different biological
ﬂuids for 4 h in serum-free media, washed, and then incubated in serum-
containing medium for 72 h before analyses of CD86 and GFP expression. Dead
cells were excluded using Live/Dead ﬁxable near-IR dead cell stain kit (Thermo-
Fisher). Flow cytometry sample data were acquired on a FACSVerse (BD Bios-
ciences) and the analysis was performed in FlowJo software (TreeStar).
Thioﬂavin-T assay. NNFGAIL, GNNQQNY, Aβ42, and Aβ40 were synthesized
and puriﬁed by Pepscan (The Netherlands) and the ﬁnal molecular weight was
veriﬁed by MS. Ten microliters of dimethyl sulfoxide (ThermoFisher, USA) were
added to 1 mg aliquots of the peptide and running stocks were prepared in MQ
water. ThT (Sigma-Aldrich) was prepared at 4 mM in MQ water. For the assay
with RSV and NNFGAIL or GNNQQNY, 50 µL of 1 mM peptide were incubated
with 150 µL of 4 mM ThT solution and 100 µL of RSV (freshly collected serum-free
RSV supernatant, not-sucrose cushion concentrated, 3 × 108 genome copy/mL),
non-infected supernatant, serum-free viral production medium (VP-SF medium),
RSV+ 5% FBS, or lipid vesicles (positively or negatively charged, dimeter= 200
nm, concentration= 1 × 1010 particles/mL in VP-SF medium). For the assay with
HSV-1 and Aβ42 or Aβ40, 50 µL of 50 µM peptide were incubated with 150 µL of 4
mM ThT solution and 100 µL of serum-free produced HSV-1 (2 × 108 PFU/mL),
non-infected supernatant, DMEM serum-free medium, HSV-1 + 5% FBS, or lipid
vesicles (positively or negatively charged, dimeter= 200 nm, concentration= 1 ×
1010 particles/mL in DMEM serum-free medium). ThT ﬂuorescence was measured
at 440 nm excitation and 480 nm emission in a black, clear-bottom 96-well plates
(Corning, USA) at 10–15 min intervals (from bottom with periodic shaking) over
12–24 h on SpectraMax i3 microplate reader (Molecular Devices, USA). Curves
were ﬁtted using GraphPad Prism software.
Electron microscopy. For cell sections with RSV, HEp-2 cells were seeded in 6 cm
dishes in maintenance medium until 70–80% conﬂuent, then washed and medium
replaced with VP-SFM with gentamycin before infecting with RSV at MOI 100 in
serum-free conditions or in 50% v/v of different biological ﬂuids. Cells were then
ﬁxed with 2.5% glutaraldehyde in 0.1 M phosphate buffer pH 7.4 at RT for 30 min.
The cells were scraped off and transferred to an Eppendorf tube and further ﬁxed
overnight in the refrigerator. After ﬁxation, cells were rinsed in 0.1 M phosphate
buffer and centrifuged (100 × g for 5 min). The pellets were then ﬁxed with 2%
osmium tetroxide (TAAB, Berks, England) in 0.1 M phosphate buffer pH 7.4 at 4 °
C for 2 h, then dehydrated in ethanol followed by acetone and embedded in LX-112
(Ladd, Burlington, Vermont, USA). Ultrathin sections (~50–60 nm) were cut by a
Leica EM UC 6 (Leica, Wien, Austria). Sections were stained with uranyl acetate
followed by lead citrate and imaged in a Tecnai 12 Spirit Bio TWIN TEM (FEI
Company, Eindhoven, The Netherlands) at 100 kV. Digital images were captured
by a Veleta camera (Olympus Soft Imaging Solutions, GmbH, Münster, Germany).
For iEM, cells were ﬁxed in 3% paraformaldehyde in 0.1 M phosphate buffer.
Samples were then rinsed with 0.1 M phosphate buffer and inﬁltrated in 10%
gelatin. Then, the specimens were inﬁltrated into 2.3 M sucrose and frozen in liquid
nitrogen. Sectioning was performed at −95 °C and mounted on carbon-reinforced
formvar-coated, 50-mesh Nickel grids. Immunolabeling was performed as follows:
grids were placed directly on drops of 2% normal goat serum (DAKO, Glostrup,
Denmark) in 0.1 M phosphate buffer to block nonspeciﬁc binding, then incubated
with the following primary antibodies: mouse anti-RSV fusion protein monoclonal
antibody (MAB8599, Millipore, USA) or goat anti-human IgG (LI-COR, USA), or
mouse anti-SP-A antibody (Abcam, ab51891). Antibodies were diluted 1:50 in 0.1
M of phosphate buffer containing 0.1% normal goat serum overnight in a humi-
diﬁed chamber at RT. The sections were washed using the same buffer and bound
antibodies were detected using secondary antibodies coated with 10 nm gold (BBI
Solution, Analytic Standard, Sweden) at a ﬁnal dilution of 1:100. Sections were then
rinsed in buffer and ﬁxed in 2% glutaraldehyde, stained with 0.05% uranyl acetate,
embedded in 1% methylcellulose, and then examined in a Tecnai G2 Bio TWIN
(FEI Company, Eindhoven, The Netherlands) at 100 kV. Digital images were
captured by a Veleta camera (Soft Imaging System GmbH, Műnster, Germany).
For TEM of viruses with amyloids, 100 µL of RSV (3 × 108 genome copies/mL) or
HSV-1 (2 × 108 PFU/mL) were incubated with 50 µL 1 mM NNFGAIL (for RSV) or
50 µM Aβ42 (for HSV-1) for 100 min at 37 °C. Samples were applied to Formvar/
carbon-coated 200-mesh nickel grids (Agar Scientiﬁc, UK), then negatively stained
using an aqueous solution of uranyl acetate (1%) and visualized.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10192-2
14 NATURE COMMUNICATIONS |         (2019) 10:2331 | https://doi.org/10.1038/s41467-019-10192-2 | www.nature.com/naturecommunications
Western blotting. Serum-free produced RSV was incubated with BALF or HP,
both at a protein concentration of 0.1 mg/mL at a ratio of 1:1 v/v (in citrate-
adjusted conditions to prevent coagulation) for 1 h at 37℃, then collected and
washed similar to the procedure for corona proteomic analysis. Samples were lysed
using a RIPA lysis buffer with protease inhibitors and protein content was mea-
sured. Samples were heated with loading buffer to 95 °C for 5 min and 1 µg of
protein was loaded onto NuPAGE® Bis-Tris 4–12% gels then separated at 80 V for
15 min followed by 100 V for 135 min at RT using 1× NuPAGE®MES SDS running
buffer (Invitrogen). The gels were then transferred onto nitrocellulose membranes
using the IBlot® system (Invitrogen) and, subsequently, the membranes were
blocked with Odyssey Blocking Buffer (LI-COR Biosciences GmbH) for 1.5 h.
Membranes were incubated overnight at 4℃ with anti-SP-A antibody [6F10]
(ab51891, Abcam) diluted at 1:500, then probed the next day using goat anti-
human IgG (IRDye 800, red, LI-COR Biosciences) and goat anti-mouse IgG
(IRDye 680, green, LI-COR Biosciences). To normalize the bands to a loading
control, scanned membranes were stripped for 10 min at 65 °C using 1× New Blot
Nitro Stripping buffer (LI-COR Biosciences), blocked for 1.5 h, and then incubated
with anti-RSV antibody (ab20745, Abcam)65 at 1:500 dilution for 2 h at RT before
probing with secondary antibody (donkey anti-goat, IRDye 680, green, LI-COR
Biosciences). All western blotting signals were scanned using the Odyssey Imager
(LI-COR Biosciences GmbH) and quantiﬁcation was performed on the images
using ImageJ software.
Animal experiments. To evaluate the impact of the HSV-1 on brain β-amyloid
(Aβ) levels, 3-month-old transgenic 5XFAD mice (purchased from Jackson
Laboratories, Bar Harbor, Maine, USA) were randomly divided into two groups.
The animals were injected either with the HSV virus or non-infected supernatant
using a micro-infusion pump (The Harvard Apparatus Pump Series, Harvard
Bioscience, USA) into the right lateral ventricles. Brieﬂy, surgical anesthesia was
induced with 5% isoﬂurane and maintained with 1.8% isoﬂurane (in 30% O2/70%
N2O). The temperature of the animals was maintained at 37 ± 0.5 °C using a
thermostatically controlled heating blanket connected to a rectal probe (PanLab,
Harvard Apparatus, Barcelona, Spain). The skin was opened and the scull exposed.
A small hole ~1 mm in diameter was drilled into the following coordinates: m/l
(medial/lateral)+ 1.1 mm, a/p (anterior/posterior) −0.3 mm, d/v (dorsal/ventral)
−2.0 mm. The mice were infused with either 10 µL of HSV-1 virus (2 × 108 PFU/
mL) or with non-infected supernatant as control. After injection, the wound was
sutured and the animals placed in individual cages to recover for 48 h. All animal
work was approved by the Animal Care and Use Committee of the University of
Eastern Finland (Kuopio) and performed according to the guidelines of National
Institutes of Health for animal care. Mice were killed at 48 h after ICV (intracer-
ebroventricular) infusion for tissue collection. The mice were anesthetized with an
overdose of Avertin followed by transcardial perfusion with heparinized saline
(2500 IU/L). The ICV-infused brain hemisphere were removed and post ﬁxed in
4% paraformaldehyde followed by cryoprotection in 30% sucrose. The hemibrains
were frozen in liquid nitrogen and cryosectioned into 20 μm sagittal sections, and
stored in the anti-freeze solution. Six consecutive sagittal brain sections at 400 μm
intervals were selected for immunohistological staining from each mouse. Aβ
deposits were detected using primary antibody speciﬁc to isoforms Aβ 37–42 (Aβ
D54D2 XP, Cell Signaling Technology, 1:100 dilution, overnight at RT) and further
visualized by ﬂuorescent Alexa 568 secondary antibody (1:500 dilution, Thermo-
Fisher Scientiﬁc). For quantiﬁcation of Aβ immunoreactivities, the stained sections
were imaged using ×10 magniﬁcation in Zeiss Axio ImagerM.2 microscope
equipped with Axiocam 506 mono charge-coupled device camera (Carl Zeiss,
Oberkochen, Germany) running ZEN software (Carl Zeiss) for tailing and stitching
of the images. Cortical and hippocampal Aβ immunoreactivities were quantiﬁed
from six stained sections at 400 µm intervals per animal using MatLab (Math-
Works, MatLab 2017b). The accuracy of the analysis was conﬁrmed by re-
analyzing the images using ImageJ 1.50i software.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article and
its supplementary information ﬁles or from the corresponding authors upon reasonable
request.
Received: 16 January 2019 Accepted: 26 April 2019
References
1. Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas
provide the biological identity of nanosized materials. Nat. Nanotechnol. 7,
779–786 (2012).
2. Walczyk, D., Bombelli, F. B., Monopoli, M. P., Lynch, I. & Dawson, K. A. What
the cell ‘sees’ in bionanoscience. J. Am. Chem. Soc. 132, 5761–5768 (2010).
3. Cai, R. & Chen, C. The crown and the scepter: roles of the protein corona in
nanomedicine. Adv. Mater. 1805740, 1805740 (2018).
4. Mortimer, G. M. et al. Cryptic epitopes of albumin determine mononuclear
phagocyte system clearance of nanomaterials. ACS Nano 8, 3357–3366 (2014).
5. Lynch, I., Dawson, K. A. & Linse, S. Detecting cryptic epitopes created by
nanoparticles. Sci. STKE 2006, pe14 (2006). https://doi.org/10.1126/
stke.3272006pe14
6. Deng, Z. J., Liang, M., Monteiro, M., Toth, I. & Minchin, R. F. Nanoparticle-
induced unfolding of ﬁbrinogen promotes Mac-1 receptor activation and
inﬂammation. Nat. Nanotechnol. 6, 39–44 (2011).
7. Linse, S. et al. Nucleation of protein ﬁbrillation by nanoparticles. Proc. Natl
Acad. Sci. USA 104, 8691–8696 (2007).
8. Habchi, J.et al. Cholester ol catalyses Aβ42 aggregation through a
heterogeneous nucleation pathway in the presence of lipid membranes. Nat.
Chem. 10, 673–683 (2018) https://doi.org/10.1038/s41557-018-0031-x
9. Gladytz, A., Abel, B. & Risselada, H. J. Gold-induced ﬁbril growth: the
mechanism of surface-facilitated amyloid aggregation. Angew. Chem. Int. Ed.
55, 11242–11246 (2016). https://doi.org/10.1002/anie.201605151
10. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dawson, K. A. & Linse, S.
Dual effect of amino modiﬁed polystyrene nanoparticles on amyloid beta
protein ﬁbrillation. ACS Chem. Neurosci. 1, 279–287 (2010).
11. Bächi, T. & Howe, C. Morphogenesis and ultrastructure of respiratory
syncytial virus. J. Virol. 12, 1173–1180 (1973).
12. Nair, H. et al. Global burden of acute lower respiratory infections due to
respiratory syncytial virus in young children: a systematic review and meta-
analysis. Lancet 375, 1545–1555 (2010).
13. McDermott, D. S., Weiss, K. A., Knudson, C. J. & Varga, S. M. Central role of
dendritic cells in shaping the adaptive immune response during respiratory
syncytial virus infection. Futur. Virol. 6, 963–973 (2011).
14. Collins, P. L. & Graham, B. S. Viral and host factors in human respiratory
syncytial virus pathogenesis. J. Virol. 82, 2040–2055 (2008).
15. Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. Immunity to and
frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163,
693–698 (1991).
16. Graham, B. S. Biological challenges and technological opportunities for RSV
vaccine development. Immunol. Rev. 239, 149–166 (2011).
17. Roizman, B. Human Herpesviruses: Biology, Therapy and Immunoprophylaxis.
(Cambridge Univ. Press, 2007). https://doi.org/10.2277/0521827140
18. Laine, R. F. et al. Structural analysis of herpes simplex virus by optical super-
resolution imaging. Nat. Commun. 6, 5980 (2015).
19. Menendez, C. M. & Carr, D. J. J. Deﬁning nervous system susceptibility during
acute and latent herpes simplex virus-1 infection. J. Neuroimmunol. 308,
43–49 (2017).
20. Santos, C. Y. et al. Pathophysiologic relationship between Alzheimer’s disease,
cerebrovascular disease, and cardiovascular risk: a review and synthesis.
Alzheimer’s Dement. (Amst.) 7, 69–87 (2017).
21. Itzhaki, R. F. Corroboration of a major role for herpes simplex virus type 1 in
Alzheimer’s disease. Front. Aging Neurosci. 10, 1–11 (2018).
22. Wozniak, M. A., Itzhaki, R. F., Shipley, S. J. & Dobson, C. B. Herpes simplex
virus infection causes cellular beta amyloid accumulation and secretase
upregulation. Neurosci. Lett. 429, 95–100 (2007).
23. Wozniak, M. A. & Itzhaki, R. F. Herpes simplex virus type 1 DNA is located
within Alzheimer’s disease amyloid plaques. J. Pathol. 220, 114–125 (2010).
24. Lövheim, H., Gilthorpe, J., Adolfsson, R., Nilsson, L.-G. & Elgh, F. Reactivated
herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers
Dement. 11, 1–7 (2014).
25. Tzeng, N. S. et al. Anti-herpetic medications and reduced risk of dementia in
patients with herpes simplex virus infections—a nationwide, population-based
cohort study in Taiwan. Neurotherapeutics 15, 417–429 (2018).
26. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects
nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772–781 (2013).
27. Whitwell, H. et al. Nanoparticles in the lung and their protein coron: the few
proteins that count. Nanotoxicology 10, 1385–1394 (2016).
28. Arosio, P., Knowles, T. P. J. & Linse, S. On the lag phase in amyloid ﬁbril
formation. Phys. Chem. Chem. Phys. 17, 7606–7618 (2015).
29. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration,
and neuron loss in transgenic mice with ﬁve familial Alzheimer’s disease
mutations: potential factors in amyloid plaque formation. J. Neurosci. 26,
10129–10140 (2006).
30. Chang, K.-S., Jiang, J., Cai, Z. & Luo, G. Human apolipoprotein e is required
for infectivity and production of hepatitis C virus in cell culture. J. Virol. 81,
13783–13793 (2007).
31. Waddington, S. N. et al. Adenovirus serotype 5 hexon mediates liver gene
transfer. Cell 132, 397–409 (2008).
32. Doronin, K. et al. Coagulation factor X activates innate immunity to human
species C adenovirus. Science 338, 795–798 (2012).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10192-2 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2331 | https://doi.org/10.1038/s41467-019-10192-2 | www.nature.com/naturecommunications 15
33. Morizono, K. et al. The soluble serum protein Gas6 bridges virion envelope
phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral
entry. Cell Host Microbe 9, 286–298 (2011).
34. Surviladze, Z., Dziduszko, A. & Ozbun, M. A. Essential roles for soluble
virion-associated heparan sulfonated proteoglycans and growth factors in
human papillomavirus infections. PLoS Pathog. 8, e1002519
(2012).
35. Münch, J. et al. Semen-derived amyloid ﬁbrils drastically enhance HIV
infection. Cell 131, 1059–1071 (2007).
36. Pitek, A. S., Wen, A. M., Shukla, S. & Steinmetz, N. F. The protein corona of
plant virus nanoparticles inﬂuences their dispersion properties, cellular
interactions, and in vivo fates. Small 12, 1758–1769 (2016) https://doi.org/
10.1002/smll.201502458
37. Taylor, G. Animal models of respiratory syncytial virus infection. Vaccine 35,
469–480 (2017).
38. Forshed, J. Experimental design in clinical omics biomarker discovery. J.
Proteome Res. 16, 3954–3960 (2017).
39. Ko, Y.-P. & Flick, M. Fibrinogen is at the interface of host defense and
pathogen virulence in Staphylococcus aureus infection. Semin. Thromb.
Hemost. 42, 408–421 (2016).
40. Blatt, A. Z., Pathan, S. & Ferreira, V. P. Properdin: a tightly regulated critical
inﬂammatory modulator. Immunol. Rev. 274, 172–190 (2016).
41. Gavins, F. N. E. & Hickey, M. J. Annexin A1 and the regulation of innate and
adaptive immunity. Front. Immunol. 3, 1–11 (2012).
42. Zackular, J. P., Chazin, W. J. & Skaar, E. P. Nutritional immunity: S100
proteins at the host-pathogen interface. J. Biol. Chem. 290, 18991–18998
(2015).
43. Mor-Vaknin, N., Punturieri, A., Sitwala, K. & Markovitz, D. M. Vimentin is
secreted by activated macrophages. Nat. Cell Biol. 5, 59–63 (2003).
44. Hickling, T. P. et al. Lung surfactant protein A provides a route of entry for
respiratory syncytial virus into host cells. Viral Immunol. 13, 125–135 (2000).
45. Tayyari, F. et al. Identiﬁcation of nucleolin as a cellular receptor for human
respiratory syncytial virus. Nat. Med. 17, 1132–1135 (2011).
46. Currier, M. G. et al. EGFR interacts with the fusion protein of respiratory
syncytial virus strain 2-20 and mediates infection and mucin expression. PLoS
Pathog. 12, 1–22 (2016).
47. Neagu, M. et al. Protein bio-corona: critical issue in immune nanotoxicology.
Arch. Toxicol. 91, 1–18 (2016).
48. Qu, H. et al. Kindlin-2 regulates podocyte adhesion and ﬁbronectin matrix
deposition through interactions with phosphoinositides and integrins. J. Cell
Sci. 124, 879–891 (2011).
49. Kuhl, B. D., Cheng, V., Wainberg, M. A. & Liang, C. Tetherin and its viral
antagonists. J. Neuroimmune Pharmacol. 6, 188–201 (2011).
50. Wickham, T. J., Granados, R. R., Wood, H. A., Hammer, D. A. & Shuler, M. L.
General analysis of receptor-mediated viral attachment to cell surfaces.
Biophys. J. 58, 1501–1516 (1990).
51. Buell, A. K. The Nucleation of Protein Aggregates - From Crystals to Amyloid
Fibrils. International Review of Cell and Molecular Biology 329 (Elsevier Inc.,
2017).
52. Mahmoudi, M., Kalhor, H. R., Laurent, S. & Lynch, I. Protein ﬁbrillation and
nanoparticle interactions: opportunities and challenges. Nanoscale 5,
2570–2588 (2013).
53. Piacentini, R. et al. HSV-1 and Alzheimer’s disease: more than a hypothesis.
Front. Pharmacol. 5, 1–9 (2014).
54. Readhead, B. et al. Multiscale analysis of independent Alzheimer’s cohorts
ﬁnds disruption of molecular, genetic, and clinical networks by human
herpesvirus. Neuron 99, 64–82 (2018). https://doi.org/10.1016/j.
neuron.2018.05.023
55. Eimer, W. A. et al. Alzheimer’s Disease-Associated β-Amyloid Is Rapidly
Seeded by Herpesviridae to Protect against Brain Infection. Neuron 99, 56–63
(2018). https://doi.org/10.1016/j.neuron.2018.06.030
56. Dominy, S. S. et al. Porphyromonas gingivalis in Alzheimer’s disease brains:
Evidence for disease causation and treatment with small-molecule inhibitors.
Sci. Adv. 5, eaau3333 (2019).
57. De Chiara, G. et al. Recurrent herpes simplex virus-1 infection induces
hallmarks of neurodegeneration and cognitive deﬁcits in mice. PLoS Pathog.
15, e1007617 (2019).
58. Wojtowicz, W. M. et al. Stimulation of enveloped virus infection by β-amyloid
ﬁbrils. J. Biol. Chem. 277, 35019–35024 (2002).
59. Kumar, D. K. V. et al. Amyloid-beta peptide protects against microbial
infection in mouse and worm models of Alzheimers disease. Sci. Transl. Med.
8, 34072–34072 (2016).
60. Clifford, D. B. & Ances, B. M. HIV-associated neurocognitive disorder. Lancet
Infect. Dis. 13, 976–986 (2013).
61. Jang, H., Boltz, D. A., Webster, R. G. & Smeyne, R. J. Viral parkinsonism.
Biochim. Biophys. Acta 1792, 714–721 (2009).
62. Mezzenga, R. & Adamcik, J. The amyloid polymorphism in the protein folding
and aggregation energy landscape. Angew. Chem. Int. Ed. 57, 8370–8382
(2018). https://doi.org/10.1002/ange.201713416
63. Condello, C. et al. Structural heterogeneity and intersubject variability of Aβ in
familial and sporadic Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 115,
E782–E791 (2018). https://doi.org/10.1073/pnas.1714966115
64. Mbiguino, A. & Menezes, J. Puriﬁcation of human respiratory syncytial virus:
superiority of sucrose gradient over percoll, renograﬁn, and metrizamide
gradients. J. Virol. Methods 31, 161–170 (1991).
65. Munday, D. C. et al. Interactome analysis of the human respiratory syncytial
virus RNA polymerase complex identiﬁes protein chaperones as important
cofactors that promote L-protein stability and RNA synthesis. J. Virol. 89,
917–930 (2015).
Acknowledgements
We acknowledge the Svenska Sällskapet för Medicinsk Forskning (SSMF) for supporting
K.E., Swedish Research Council (K2015–99 ×−22880-01-6) and Stockholm University
for supporting A.-L.S., Vetenskapsrådet, SSMF, and the Swedish foundation for Strategic
Research for supporting S.E.L.A., Dr. Michael N. Teng at the University of South Florida
for providing the RSV-GFP virus, Professor Arto Urtti at the University of Helsinki for
the lipid vesicles, the Instumentarium Science Foundation for supporting O.K.K., the
service of the Electron Tomography Facility at Karolinska Institutet, and the Academy of
Finland for supporting the research of T.M. A.L. obtained project funding from the
Swedish Heart-Lung Foundation (No. 20150303), the Swedish Research Council (No.
2016–01653), as well as federal funding from Karolinska Institutet and through the
Regional Agreement on Medical Training and Clinical Research (ALF, No. 20140309)
between Stockholm County Council and Karolinska Institutet. No funding was obtained
from the tobacco industry.
Author contributions
K.E. conceived the concept, designed, performed and analyzed experiments, and wrote
the paper. M.P. designed, conducted, and analyzed proteomics experiments. S.P. con-
ducted and analyzed moDC experiments and FACS data. T.R. analyzed proteomics data.
P.J. designed, performed, and analyzed moDC experiments. A.D. conducted initial RSV
propagation. B.B. performed and analyzed FACS experiments. M.J.S. and J.K.S. provided
HSV-1 stocks. B.L., M.S., and A.L. provided BALF samples. E.A.T. provided MP samples.
O.S. performed and analyzed western blotting experiments. O.K.K. and T.L. synthesized,
characterized, and provided lipid vesicles. E.S.E. and C.N. provided jHP samples. Y.I. and
T.M. designed, performed, and analyzed animal experiments. S.M. performed electron
microscopy experiments. M.J.A.W., U.F.P., J.L., and S.E.L.A. provided critical feedback.
A.-L.S. designed and analyzed experiments, and provided critical feedback. All authors
read and commented on the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-10192-2.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks Carl Walkey and
other anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10192-2
16 NATURE COMMUNICATIONS |         (2019) 10:2331 | https://doi.org/10.1038/s41467-019-10192-2 | www.nature.com/naturecommunications
